Iterum therapeutics plc (ITRM)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Revenue

-

0

0

0

37

239

254

185

191

159

-

Operating expenses:
Research and development

9,743

20,882

28,066

24,439

17,387

21,460

22,583

13,725

10,879

7,434

5,290

General and administrative

3,151

2,296

2,933

2,939

3,116

2,723

2,657

1,886

1,515

1,021

1,123

Total operating expenses

12,894

23,178

30,999

27,378

20,503

24,183

25,240

15,611

12,394

8,455

6,413

Operating loss

-12,894

-23,178

-30,999

-27,378

-20,466

-23,944

-24,986

-15,426

-12,203

-8,296

-6,413

Interest expense, net

-2,596

-406

-216

-135

-104

-297

-138

-76

85

123

46

Private placement transaction costs

2,130

-

-

-

-

-

-

-

-

-

-

Adjustments to fair value of derivatives

1,679

-

-

-

-

-

-

-

-

-

-

Other (expense) / income, net

-38

-8

48

32

124

189

328

-177

61

90

165

Total other (expense) / income

-3,085

-414

-168

-103

20

-108

190

-253

146

213

211

Loss before income taxes

-15,979

-23,592

-31,167

-27,481

-20,446

-24,052

-24,796

-15,679

-12,057

-8,083

-6,202

Income tax expense

121

49

104

157

134

206

109

68

89

88

78

Net loss and comprehensive loss

-16,100

-23,641

-31,271

-27,638

-20,580

-24,258

-24,905

-15,747

-12,146

-8,171

-6,280

Net loss attributable to ordinary shareholders

-16,100

-23,641

-31,271

-27,638

-20,580

-24,258

-24,905

-15,747

-12,146

-8,171

-6,280

Net loss per share attributable to ordinary shareholders – basic and diluted

-1.08

-1.58

-2.15

-1.93

-1.44

56.53

-1.77

-2.22

-61.36

-44.16

-39.44

Weighted average ordinary shares outstanding – basic and diluted

14,868

14,870

14,571

14,340

14,290

13,618

14,034

7,085

197

185

159